Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | LCAT | P04180 | 2/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL414299 | 0.93 | ATM (0.44) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL12042000 | 0.87 | HTT (0.48) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL414029 | 0.86 | HTT (0.47) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL414298 | 0.81 | HTT (0.45) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL13447349 | 0.73 | ATM (0.59) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL18711350 | 0.72 | ATM (0.52) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL2119090 | 0.72 | ATM (0.52) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL12059838 | 0.71 | ATM (0.39) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL18702081 | 0.70 | ATM (0.50) | ATMHTTALDH1A1MEN1KMT2A | |
| SCHEMBL15025447 | 0.70 | ATM (0.59) | ATMHTTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | ATM 4691/4885HTT 156/4885ALDH1A1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.